Publications by authors named "G Kok"

Aminoacyl-tRNA synthetases (ARSs) couple tRNAs with their corresponding amino acids. While ARSs can bind structurally similar amino acids, extreme specificity is ensured by subsequent editing activity. Yet, we found that upon isoleucine (I) restriction, healthy fibroblasts consistently incorporated valine (V) into proteins at isoleucine codons, resulting from misacylation of tRNAIle with valine by wildtype IARS1.

View Article and Find Full Text PDF

Background: South Africa (SA) has committed to eliminating malaria by 2028. However, the initial target was set for 2023. Additionally, the ongoing COVID-19 pandemic and the emergence of drug and insecticide resistance have been identified as potential stumbling blocks in the achievement of this goal.

View Article and Find Full Text PDF

Purpose: The management of indeterminate thyroid nodules remains a topic of ongoing debate, particularly regarding the differentiation of malignancy. Somatic mutation analysis offers crucial insights into tumor characteristics. This study aimed to assist the clinical management of indeterminate nodules with somatic mutation analysis.

View Article and Find Full Text PDF

Purpose: To compare 1-year outcomes of eyes with diabetic macular edema (DME) treated in routine clinical practice based on the proportion of visits where intravitreal VEGF inhibitor injections were delivered.

Design: Cohort study.

Participants: There were 2288 treatment-naive eyes with DME starting intravitreal VEGF inhibitor therapy from October 31, 2015 to October 31, 2021 from the Fight Retinal Blindness! international outcomes registry.

View Article and Find Full Text PDF
Article Synopsis
  • Hypertension (HPT) has become a major health issue in Ghana, shifting from a focus on communicable diseases to addressing non-communicable diseases amid rising prevalence rates.
  • A cost of illness framework was utilized to estimate the financial burden of treating HPT in Ghana, accounting for serious complications and employing a decision analytic model to simulate patient outcomes.
  • The study indicates a significantly high lifetime treatment cost for HPT (approximately GHS 869,106 or USD 119,056), along with an increasing mortality risk over the years, highlighting the need for targeted health policies and financial planning.
View Article and Find Full Text PDF